repaglinide 2 MG Oral Tablet

1 INDICATIONS AND USAGE Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Repaglinide tablets are a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1) Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis (1)

american health packaging

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] off label use` `[3] fatigue` `[4] nausea` `[5] diarrhoea` `[6] headache` `[7] dyspnoea` `[8] pain` `[9] condition aggravated` `[10] vomiting`

4 years ago

ROUND PINK C 747

16 HOW SUPPLIED/STORAGE AND HANDLING Repaglinide tablets, USP, 1 mg are available in the following form: yellow, round, biconvex tablets, debossed with “745” on one side and ‘C’ on the other side. Unit dose packages of 30 (5 x 6) NDC 68084-954-25 Repaglinide tablets, USP, 2 mg are available in the following form: pink, round, biconvex tablets, debossed with “747” on one side and ‘C’ on the other side. Unit dose packages of 30 (5 x 6) NDC 68084-967-25 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture. FOR YOUR PROTECTION: Do not use if blister is torn or broken.

More pills like ROUND C 747

Related Pills

repaglinide 1 MG Oral Tablet

american health packaging

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site